Longboard Pharmaceuticals

Longboard Pharmaceuticals

  • Founded: 2020
  • Location: La Jolla, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1b/Clin2a
  • Therapy area: Developmental and epileptic encephalopathies, other epilepsies
  • Drug types: NEU
  • Lead product: LP352
  • Product link: https://www.longboardpharma.com/our-approach/#pipeline
  • Funding: $23M stock Feb 2023; $80M IPO Mar 2021; $56M A Oct 2020



job board

Short description:

Novel central nervous system-targeted assets

Drug notes:

LP659 Clin0 neurological diseases; LP143 RD undisclosed; nelotanserin RD undisclosed

Long description:

Longboard Pharmaceuticals is developing therapies for patients with neurological and rare diseases. Many important categories of drugs target G protein-coupled receptors (GPCRs) that regulate various biological processes within cells. Longboard was conceived to advance a portfolio of drugs that are highly selective for GPCs using their expertise in drug development and optimization. Their lead program, LP352, is an oral small molecule that binds the GPCR 5-HT2C, which Longboard is testing as a treatment of seizures associated with patients with Developmental and Epileptic Encephalopathy syndromes.


Longboard Pharmaceuticals
Director, Scientific Communications
La Jolla, CA|15 days ago
Longboard Pharmaceuticals
Vice President, Clinical Development
La Jolla, CA|15 days ago
Longboard Pharmaceuticals
Director/Senior Director, Clinical QA & Compliance...
La Jolla, CA|15 days ago
Longboard Pharmaceuticals
Senior Manager, Accounting
La Jolla, CA|15 days ago
Longboard Pharmaceuticals
Director, Clinical Bioanalysis
La Jolla, CA|17 days ago
Longboard Pharmaceuticals
Senior Scientist / Associate Director, Preclinical...
United States|17 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com